Edwards Lifesciences (EW) announced one-year data highlighting the continued performance of its SAPIEN 3 Ultra RESILIA valve. The data were ...

Designed for patients needing a replacement valve, the company’s TAVI trial has found low rates of mortality after a year of ...

Analyst Josh Jennings from TD Cowen maintained a Hold rating on Edwards Lifesciences (EW – Research Report) and keeping the price target at ...

Edwards Lifesciences (NYSE:EW) today announced one-year data highlighting strong performance from its Sapien 3 Ultra Resilia ...

Edwards Lifesciences (NYSE: EW) today announced one-year data highlighting the continued outstanding performance of its SAPIEN 3 Ultra RESILIA valve. The data were presented at PCR London Valves 2024 ...

JPMorgan keeps an Overweight rating on Edwards Lifesciences (EW) after the company reported results from the EARLY TAVR trial, the first of its kind studying Sapien 3 in asymptomatic severe aortic ...

Edwards Lifesciences Receive the the latest news, research, and presentations from major meetings right to your inbox. TCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is ...

According to results from the CAVEAT study, the short-frame, balloon-expandable Sapien 3 and Sapien Ultra (Edwards Lifesciences) transcatheter heart valves had the highest rates of preserved left and ...

Half of the study’s participants received the physician’s choice of either Edwards Lifesciences’ Sapien 3 or Medtronic’s Evolut family. The trial was the largest to date of Acurate neo2 ...

Bank of New York Mellon Corp increased its position in shares of Edwards Lifesciences by 4.3% during the second quarter ...